Bioprocess Filtration Patents: Leaders, Trends & White Space 2026
- Filing has peaked, not accelerated. Filings climbed from 18 in 2017 to a peak of 39 in 2024, but the 2022 midpoint of 27 shows growth was already flattening before the peak — this is a maturing claim space, not a land grab.
- Separation and protein chemistry dominate the IPC mix. B01D (372 records) and C07K (235 records) between them touch most of the corpus, while C12N, A61K and A61M sit far behind — the technical center of gravity is membrane separation feeding protein purification, not upstream bioreactor design.
- The most-cited art is decades old. The two highest-cited records, both titled around tangential flow filtration apparatus, carry 236 and 171 citations — foundational filings that still shape freedom-to-operate analysis for anyone filing single-pass or recirculating TFF claims today.
Filing growth compares 2021 (36 records) with 2024 (39) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 553 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Bioprocess filtration and downstream purification sits at the intersection of membrane separation and biopharmaceutical manufacturing: tangential flow filtration, viral clearance steps, single-use systems and continuous processing all show up in this corpus because they solve the same problem — getting a therapeutic protein out of a bioreactor harvest at commercial yield without fouling the membrane or losing product to the wrong side of it. The search combines bioprocess filtration and downstream purification terminology with IPC coverage across B01D61 (separation processes), C07K1 (peptide and protein purification) and C12M1 (bioreactor apparatus), so it captures both the hardware and the protein-chemistry side of the same manufacturing step.
553 published families span 2015 through mid-2026, with receiving offices concentrated in the United States, Europe and the WIPO PCT route, plus meaningful India, Australia and Canada filing — consistent with a technology that has to clear regulatory and manufacturing jurisdictions well beyond its country of invention.
Filing trend and technology composition
Two views of the same 553-family dataset: how filing volume has moved year over year, and which IPC subclasses carry the technical weight.
Filings rose then flattened
From 18 filings in 2017 to a peak of 39 in 2024, with the 2022 midpoint of 27 showing the growth curve had already leveled before the peak. 2025 and 2026 figures are undercounts by construction — publication lags filing by roughly 18 months, so the most recent two years will revise upward as later applications publish.
Separation and protein chemistry lead
B01D (372 records) and C07K (235) dominate; C12M (138) and C12N (66) trail as the bioreactor and microorganism side of the pipeline; A61K, G01N, A61M and A23J each register in the tens, marking narrower application niches rather than core claim territory.
Shares are the percentage of the 553 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Bioprocess Filtration and Downstream Purification with Eureka
This page is one run against one query. Ask Eureka your own question about bioprocess filtration and downstream purification and every answer comes back with the patent numbers behind it.
Try EurekaThe patents everyone in this space cites
US10350518B2 — Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
Methods of filtering a liquid feed are disclosed. In one version, the method comprises passing a liquid feed through a single pass tangential flow filtration (SPTFF) system and recovering the retentate and permeate from the system in separate containers without recirculation through the SPTFF system. In another version, the method of filtering a liquid feed comprises passing a liquid feed through a tangential flow filtration (TFF) system, recovering permeate and a portion of the retentate from the system in separate containers without recirculation through the TFF system, and recirculating the remainder of the retentate through the TFF system at least once.Assigned to EMD Millipore Corporation, granted 2019-07-16.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5256294A | Tangential flow filtration process and apparatus | 236 |
| 2 | US5490937A | Tangential flow filtration process and apparatus | 171 |
| 3 | US20040167320A1 | Methods of tangential flow filtration and an apparatus therefore | 137 |
| 4 | US20070246406A1 | Tangential flow filtration apparatuses, systems, and processes for the separation of compounds | 127 |
| 5 | US6268487B1 | Purification of biologically active peptides from milk | 119 |
| 6 | WO2006110277A1 | Protein purification using HCIC AMD ion exchange chromatography | 90 |
| 7 | US20060246544A1 | Manufacturing process for the production of peptides grown in insect cell lines | 89 |
| 8 | US20050197496A1 | Methods of protein fractionation using high performance tangential flow filtration | 79 |
| 9 | WO2007108955A1 | Protein purification | 66 |
| 10 | US6312591B1 | Filtration cell for tangential flow filtration and filtration system making use of such cell | 58 |
Citation counts inside a searched corpus skew toward older filings simply because they have had longer to accumulate references — read this as a map of influence on claim drafting, not a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data actually tells you
Three readings of the same evidence, aimed at the questions that actually change a filing or freedom-to-operate decision.
A matured claim space, not a growth story
The climb to a 2024 peak with a flat 2022 midpoint suggests the core tangential flow filtration and viral clearance claim territory filled up years ago. New entrants are more likely to be filing around the edges of existing claims than staking fresh ground.
Membrane hardware outweighs protein chemistry claims
B01D separation-process filings outnumber C07K peptide-purification filings by a wide margin, which points to more claim pressure on filtration apparatus and process parameters than on the biochemistry of what is being purified.
Foundational TFF apparatus patents still anchor the field
The two most-cited records both cover tangential flow filtration process and apparatus fundamentals. Any new single-pass or recirculating TFF claim is likely to be evaluated against this foundational art first.
Co-filing is rare and concentrated
Only ten co-assignee pairs appear across 553 families, with one pairing appearing eight times — collaboration in this space is the exception, and most filings are made by a single assignee acting alone.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bioprocess filtration and downstream purification, with the prior art for and against each one.
Who is filing, and who has slowed down
Recent-year momentum matters more than cumulative counts here: several assignees with large historical portfolios show zero or negative filing activity in the latest year, which changes how their claims should be weighted in a freedom-to-operate check.
Genentech keeps filing while others pause
Genentech shows 2 filings in the latest year, a small number in absolute terms but notable against a field where most tracked assignees show zero recent activity — worth watching for where its next claims land.
Repligen's filing pace has dropped sharply
Repligen recorded 1 filing in the latest year against a 67% year-over-year decline, suggesting either a pause in new claim activity or a shift in filing strategy away from the tracked claim scope.
Large incumbents have gone quiet in this dataset
EMD Millipore, Genzyme, Amgen and F. Hoffmann-La Roche all show zero filings in the latest tracked year, including a 100% year-over-year drop for Amgen. Their existing granted claims still matter for freedom-to-operate, but their active claim-shaping influence has receded.
| Assignee | Recent year | YoY |
|---|---|---|
| Genentech, Inc. | 2 | — |
| Repligen Corporation | 1 | -67% |
| EMD Millipore Corporation | 0 | — |
| Genzyme Corporation | 0 | — |
| Amgen Inc. | 0 | -100% |
| F. Hoffmann-La Roche Ltd | 0 | — |
| Medarex, Inc. | 0 | — |
| Sartorius Stedim Biotech GmbH | 0 | -100% |
Where to take this analysis
The trend and assignee data point to specific next questions depending on whether you are clearing a filing or scoping a design-around.
Check freedom-to-operate against foundational TFF art
Before drafting new tangential flow filtration or single-use system claims, run the most-cited records here against your specific process parameters — recirculation ratios, pass counts and retentate handling are where overlap is most likely.
Explore the citation network in EurekaWatch the quiet incumbents for reactivation
Several assignees with large historical portfolios show zero recent filings. A licensing or acquisition move by any of them would shift the competitive picture faster than organic filing growth would.
Track assignee activity in EurekaScope claims in the under-claimed branches
Fouling-resistant surface chemistry and continuous-processing integration show thinner filing density than core TFF hardware — these are the branches most likely to still accept a strong first claim.
Draft a claim scope in EurekaCommon questions about this landscape
The most-cited records in this dataset are two apparatus patents around tangential flow filtration process design, cited 236 and 171 times respectively, along with a family of related filtration apparatus and process claims. These foundational patents still shape how new single-pass and recirculating TFF systems get drafted, because most later filings position their claims relative to this earlier art. Anyone filing a new TFF claim should expect examiners and competitors to cite this cluster first.
Filing volume rose from 18 in 2017 to a peak of 39 in 2024, but the midpoint year of 2022 already showed 27 filings, indicating the growth curve had flattened before the peak rather than accelerating into it. That pattern is more consistent with a maturing, well-occupied claim space than an emerging one. Recent-year counts for 2025 and 2026 should be read as undercounts, since publication typically lags filing by around 18 months.
Recent-year momentum data shows most large historical assignees, including EMD Millipore, Genzyme, Amgen and F. Hoffmann-La Roche, at zero filings in the latest tracked year, while Genentech shows a small but positive count of 2 and Repligen shows 1 filing down 67% year over year. This suggests active claim-shaping has shifted toward a smaller group of currently filing assignees even though the largest cumulative portfolios belong to companies that have gone quiet recently. Zero recent filings does not mean an assignee has exited the market, only that new patent claims are not the current focus.
US10350518B2, assigned to EMD Millipore Corporation and granted in 2019, covers methods of filtering a liquid feed using single-pass tangential flow filtration (SPTFF) without recirculation, and separately, methods using a TFF system that recirculates a portion of the retentate at least once before recovery. The claims center on how permeate and retentate are recovered and whether or how the retentate is recirculated through the system. Anyone designing a TFF process needs to check whether their recirculation strategy and container-separation approach falls inside these two claimed variants.
Filing density is thin relative to the core TFF and protein-purification claims in areas like fouling-resistant membrane surface chemistry, continuous-processing integration with single-use systems, and viral clearance validation specifically for continuous downstream trains. These branches sit adjacent to heavily filed core claims in B01D and C07K but have not attracted the same density of protection. A first claim in one of these areas would likely need to tie a specific surface chemistry or validation method to a named process step rather than claiming the general concept, since the general concepts are already well covered.
Research Bioprocess Filtration and Downstream Purification in depth with Eureka
Go past this page: query the whole bioprocess filtration and downstream purification corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.